Media & Resources

NEW YORK — Scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) have discovered a new vulnerable site on HIV that antibodies can attack to prevent infection from a broad range of the virus’ many variants. “HIV has very few known sites of vulnerability, but in this work we’ve described…

Written Testimony to the U.S. House Appropriations Subcommittee on State, Foreign Operations and Related Programs on the FY 2015 President’s Budget Request Submitted by Margaret G. McGlynn, President and CEO of IAVI.

Dedicated Physician-Scientist, Champion of the Global Fight against HIV / AIDS.

IAVI, the International AIDS Vaccine Initiative, congratulates the researchers behind a landmark study mapping the evolution of a broadly neutralizing antibody (bNAb) against HIV. The study — by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health; Columbia University; the Centre for the AIDS Programme…

NEW YORK, November 30, 2007 – In honor of World AIDS Day on December 1, the International AIDS Vaccine Initiative (IAVI) and Yahoo! have joined forces to raise US$100,000 to support pioneering technologies for AIDS vaccine research. IAVI and Yahoo! encourage individuals around the world to make a contribution aimed at ending the AIDS pandemic.…

NEW YORK, November 29, 2007—In advance of World AIDS Day on December 1, the International AIDS Vaccine Initiative (IAVI) announced that BD, a global medical technology company, will provide the non-profit organization with US$900,000 in cash, equipment and medical supplies over a three–year period. BD’s support, a 50-percent increase on an annual basis over its…

Epidemic requires a vaccine. Perseverance and innovation are key. Volunteers are heroes.

Henry Schein, Inc. Joins BD, Continental Airlines, Google, Merck and Pfizer in the Search for an AIDS Vaccine.